Drug Profile
Research programme: plant-derived antibiotics - 21st Century Therapeutics/Oxford Pharmaceuticals
Alternative Names: Anti-methicillin-resistant staphylococcus aureus antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Anti-MRSA antibiotic - 21st Century Therapeutics/Oxford Pharmaceuticals; Botanical antibiotic - 21st Century Therapeutics; KCR; Natural product antibiotics - 21st Century TherapeuticsLatest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator Oxford Pharmaceuticals
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Methicillin-resistant Staphylococcus aureus infections in USA (unspecified route)
- 28 Mar 2018 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA